Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIKture-01: OKI-219 in Advanced Solid Tumors and Breast Cancer
NCT06239467Phase 1Active, not recruiting
- Sponsor
- OnKure Therapeutics
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of OKI-219 in solid tumor and breast cancer (9 arms), sponsored by OnKure Therapeutics. Primary endpoints: Maximum Tolerated Dose at 28 days, Serious Adverse Events at 1 year and 2 more. Started Feb 2024; status: active, not recruiting.
02
Drugs
OKI-219
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT06239467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06239467.